Company to continue seeking non-dilutive funding for Bundibugyo Ebola vaccine program
Soligenix to actively evaluate strategic options including partnerships, licensing, and M&A
Company says cash position provides runway into Q2 2028
Overview
US biopharmaceutical firm's Q2 net loss narrowed due to reduced R&D expenses
Company reported no revenue for Q2 2026
Result drivers
Lower R&D expenses - Net loss narrowed mainly due to reduced research and development costs after terminating the FLASH2 trial and HyBryte development activities
Analyst coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Soligenix Inc is $1.75, about 362% above its August 6 closing price of $0.38
SNGX•
